Dr. Formenti on Combining Radiotherapy With Immunotherapy in NSCLC

Silvia Formenti, MD
Published: Thursday, Jan 07, 2016



Silvia Formenti, MD, chair of Radiation Oncology at Weill Cornell Medical College and radiation oncologist-in-chief at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses combining radiotherapy with immunotherapy in non-small cell lung cancer (NSCLC).

Previous studies investigating anti–CTLA-4 monoclonal antibodies had failed to demonstrate a significant impact in NSCLC, says Formenti. However, when ipilimumab was combined with radiotherapy a 33% objective response rate was demonstrated in patients with NSCLC.

Patients who responded compared to those who did not had some evidence of immunization, as demonstrated by circulating lymphocytes, says Formenti. 

 


Silvia Formenti, MD, chair of Radiation Oncology at Weill Cornell Medical College and radiation oncologist-in-chief at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses combining radiotherapy with immunotherapy in non-small cell lung cancer (NSCLC).

Previous studies investigating anti–CTLA-4 monoclonal antibodies had failed to demonstrate a significant impact in NSCLC, says Formenti. However, when ipilimumab was combined with radiotherapy a 33% objective response rate was demonstrated in patients with NSCLC.

Patients who responded compared to those who did not had some evidence of immunization, as demonstrated by circulating lymphocytes, says Formenti. 

 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x